Article
DiviTum Assay May Provide Earlier Evidence of Cancer Treatment Efficacy
Author(s):
Biovica’s DiviTum assay offers noninvasive tool to monitor efficacy of CDK4/6 inhibitors.
New data from an ongoing clinical trial demonstrates that the DiviTum assay can be a practical, noninvasive tool for monitoring the efficacy of CDK4/6 inhibitors.
The biomarker assay is designed to monitor and predict treatment response in cancer therapy, by measuring the activity of the thymidine kinase-I (TK) activity in blood serum or cell cultures.
The data includes a DiviTum analysis of the first 20 patients with solid tumors. Blood samples were obtained from patients before and during treatment with palbociclib (Ibrance) in combination with a MEK-inhibitor.
Changes in TKA measured by DiviTum significantly reflected mode of action response to palbociclib, according to a press release.
An abstract on DiviTum analysis of TKA and TK release in response to palbociclib in cellular extracts, tissue culture media, and mice models, was presented at the 2017 American Association for Cancer Research Annual meeting.
“The results provide guidance for using DiviTum as a test to gain early information on the response to palbociclib,” Dr Geoffrey Shapiro, MD, PhD, director of the Early Drug Development Center at the Dana-Farber Cancer Institute, said in a press release. “We look forward to including more patients in the study and providing more evidence for DiviTum as a noninvasive assay for patients treated with CDK4/6 inhibitors.”
The abstract supports DiviTum as a practical and noninvasive tool to help monitor the efficacy of CDfk4/6 inhibitors in both preclinical models and patients.
“These results, adding to the results presented at the SABCS in December 2016, further strengthens the evidence that DiviTum can indicate response to CDK4/6 treatments,” Anders Rylander, CEO of Biovica, said in the release. “There is no evidence from cell lines, animal models, patients with breast cancer, and other solid tumors including lung cancer. Going forward, we’ll continue building solid evidence of the value DiviTum can bring to patients and health care providers.”
